{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:28:05Z","timestamp":1788269285748,"version":"build-2803163510"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105330","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:26:38Z","timestamp":1775579198000},"page":"105330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Advances in current and emerging immunotherapies for ovarian cancer"],"prefix":"10.1016","volume":"223","author":[{"given":"Fan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105330_bib1","article-title":"Double-blind randomized Phase 2 trial testing personal cancer vaccines in patients with advanced ovarian cancer","volume":"13","author":"Abaid","year":"2025","journal-title":"Vaccin. (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105330_bib2","doi-asserted-by":"crossref","first-page":"S1702","DOI":"10.1016\/j.annonc.2025.09.056","article-title":"LBA44 Durvalumab + paclitaxel\/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance in patients with newly diagnosed non-tBRCA-mutated advanced ovarian cancer: Final overall survival from DUO-O\/ENGOT-ov46\/GOG-3025","volume":"36","author":"Aghajanian","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib3","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2419888122","article-title":"Triple checkpoint blockade of PD-1, Tim-3, and Lag-3 enhances adoptive T cell immunotherapy in a mouse model of ovarian cancer","volume":"122","author":"Alencar","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105330_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2113697","article-title":"A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer","volume":"11","author":"Avanzino","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105330_bib5","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1038\/s41467-020-18962-z","article-title":"Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients","volume":"11","author":"Block","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105330_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41467-025-56482-w","article-title":"The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial","volume":"16","author":"Block","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105330_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens14020140","article-title":"Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review","volume":"14","author":"Borella","year":"2025","journal-title":"Pathogens"},{"key":"10.1016\/j.critrevonc.2026.105330_bib8","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105330_bib9","doi-asserted-by":"crossref","DOI":"10.21037\/gpm-23-53","article-title":"Beyond immunotherapy-treatment advances in cell-based therapy for ovarian cancer and associated challenges","volume":"7","author":"Cao","year":"2024","journal-title":"Gynecol. Pelvic Med"},{"key":"10.1016\/j.critrevonc.2026.105330_bib10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian Cancer: A Review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105330_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s42003-024-05826-1","article-title":"Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer","volume":"7","author":"Chai","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib12","article-title":"BiTE-secreting T cells rationally combine with PD-1 blockade and vaccine boosting to reshape antitumor immunity in ovarian cancer","author":"Chiello","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105330_bib13","doi-asserted-by":"crossref","first-page":"S719","DOI":"10.1016\/j.annonc.2025.08.1711","volume":"36","author":"Cibula","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7534","article-title":"A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer","volume":"11","author":"Crawford","year":"2019","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105330_bib15","article-title":"CAR-T cell therapy in ovarian cancer: where are we now?","volume":"14","author":"Cutri-French","year":"2024","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105330_bib16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105330_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1104547","article-title":"Understanding CAR T cell therapy and its role in ovarian cancer and peritoneal carcinomatosis from ovarian cancer","volume":"13","author":"Dominguez-Prieto","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ygyno.2025.11.006","article-title":"Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial","volume":"204","author":"Evert","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14622416.2025.2580271","article-title":"Cancer genetics and response to oncolytic virus treatment for ovarian cancer","volume":"26","author":"Fletcher","year":"2025","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.critrevonc.2026.105330_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib21","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.21.01801","article-title":"Phase Ib study of navicixizumab plus paclitaxel in patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer","volume":"40","author":"Fu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib22","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105330_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12079-022-00698-8","article-title":"Friend and foe: the regulation network of ascites components in ovarian cancer progression","volume":"17","author":"Geng","year":"2023","journal-title":"J. Cell Commun. Signal"},{"key":"10.1016\/j.critrevonc.2026.105330_bib24","article-title":"Vaccination and personalized cancer vaccines focusing on common cancers in women: a narrative review","volume":"270","author":"Ghahfarrokhi","year":"2025","journal-title":"Pathol. Res Pr."},{"key":"10.1016\/j.critrevonc.2026.105330_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","article-title":"Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach","volume":"21","author":"Ghisoni","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ygyno.2024.04.001","article-title":"Adoptive T cell therapy for ovarian cancer","volume":"186","author":"Gitto","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib27","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1535-7163.MCT-20-0985","article-title":"Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of dilpacimab in patients with advanced solid tumors","volume":"20","author":"Gordon","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105330_bib28","first-page":"5552","article-title":"A phase I single-arm, open-label trial of engineering tumor-infiltrating lymphocytes with membrane-bound IL-7 for recurrent ovarian cancer","volume":"42","author":"Guo","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105330_bib29","first-page":"2536","article-title":"Phase Ib\/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors","volume":"41","author":"Guo","year":"2023"},{"key":"10.1016\/j.critrevonc.2026.105330_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2024.07.675","article-title":"Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: a randomized, multicenter clinical trial","volume":"189","author":"Gupta","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib31","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.it.2024.12.006","article-title":"Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments","volume":"46","author":"Gupta","year":"2025","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib32","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/1538-7445.AM2025-648","article-title":"Abstract 648: Activity of BNT327\/PM8002 (PD-L1 x VEGF-A bispecific antibody) in combination with BNT325\/DB-1305 (TROP2 ADC) in solid tumors: Early preclinical and clinical evidence to support BNT327 + ADC combinations","volume":"85","author":"Hamilton","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105330_bib33","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.annonc.2025.05.009","article-title":"Dostarlimab and niraparib in primary advanced ovarian cancer","volume":"36","author":"Hardy-Bessard","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib34","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","author":"Harter","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib35","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamaoncol.2023.1007","article-title":"Clinical activity of olvimulogene nanivacirepvec-primed immunochemotherapy in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer: the nonrandomized Phase 2 VIRO-15 clinical trial","volume":"9","author":"Holloway","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib36","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1136\/ijgc-2023-004812","article-title":"A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant\/refractory ovarian cancer","volume":"33","author":"Holloway","year":"2023","journal-title":"Int J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1675807","article-title":"Beyond CAR-T cells: exploring CAR-NK, CAR-M, and CAR-gammadelta T strategies in solid tumor immunotherapy","volume":"16","author":"Hou","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","article-title":"Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy","volume":"18","author":"Hu","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib39","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1158\/1078-0432.CCR-23-2864","article-title":"Anti-4-1BBxPDL1 bispecific antibody reinvigorates tumor-specific exhausted CD8+ T cells and enhances the efficacy of Anti-PD1 Blockade","volume":"30","author":"Jeon","year":"2024","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105330_bib40","article-title":"Dual-target CAR-T therapy for ovarian cancer: synergistic targeting of MSLN and B7H3 enhances anti-tumor efficacy and overcomes antigen heterogeneity","author":"Ji","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105330_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114919","article-title":"B4M3 CAR-T cell enhance antitumor activity and non-tumor toxicity in ovarian cancer","volume":"159","author":"Ji","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib42","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10637-018-0665-y","article-title":"A first-in-human phase 1a study of the bispecific anti-DLL4\/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors","volume":"37","author":"Jimeno","year":"2019","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.critrevonc.2026.105330_bib43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13046-024-03219-0","article-title":"Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors","volume":"43","author":"Jirovec","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105330_bib44","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1080\/14796694.2024.2386922","article-title":"TEDOVA: vaccine OSE2101 +\/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer","volume":"20","author":"Kabirian","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib45","doi-asserted-by":"crossref","first-page":"A065","DOI":"10.1158\/1538-7445.OVARIAN25-A065","article-title":"Abstract A065: Chimeric antigen receptor (CAR-T) cell therapy in ovarian cancer: challenges and strategies for overcoming therapeutic barriers","volume":"85","author":"Kadirr","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105330_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17233862","article-title":"Natural Killer (NK) cell-based therapies have the potential to treat ovarian cancer effectively by targeting diverse tumor populations and reducing the risk of recurrence","volume":"17","author":"Kaur","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105330_bib47","doi-asserted-by":"crossref","first-page":"S730","DOI":"10.1016\/j.annonc.2025.08.1730","article-title":"1092P Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in patients with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: durable long-term survival from the OPEB-01\/APGOT-OV4 trial","volume":"36","author":"Kim","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102891","article-title":"Melanoma-associated antigen A4: A cancer\/testis antigen as a target for adoptive T-cell receptor T-cell therapy","volume":"134","author":"Knafler","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105330_bib49","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm Phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib50","first-page":"436","article-title":"Transforming treatment paradigms: focus on personalized medicine for high-grade serous ovarian cancer","volume":"75","author":"Kordowitzki","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105330_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010565","article-title":"First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer","volume":"13","author":"Lakhani","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib52","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041314","article-title":"The emerging role of the single-cell and spatial tumor microenvironment in high-grade serous ovarian cancer","volume":"13","author":"Launonen","year":"2023","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.critrevonc.2026.105330_bib53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40364-025-00757-3","article-title":"Extracellular matrix: unlocking new avenues in cancer treatment","volume":"13","author":"Lee","year":"2025","journal-title":"Biomark. Res"},{"key":"10.1016\/j.critrevonc.2026.105330_bib54","article-title":"Innate immune cells in tumor microenvironment: a new frontier in cancer immunotherapy","volume":"27","author":"Li","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.critrevonc.2026.105330_bib55","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1016\/j.apsb.2024.06.003","article-title":"I n situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and metastases","volume":"14","author":"Li","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2026.105330_bib56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11596-023-2753-2","article-title":"Efficacy of bispecific antibody targeting EpCAM and CD3 for immunotherapy in ovarian cancer ascites: an experimental study","volume":"43","author":"Li","year":"2023","journal-title":"Curr. Med Sci."},{"key":"10.1016\/j.critrevonc.2026.105330_bib57","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12929-024-00998-8","article-title":"Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies","volume":"31","author":"Li","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.critrevonc.2026.105330_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.critrevonc.2026.105330_bib59","first-page":"12060","article-title":"An anti-EpCAM x anti-CD3 bispecific antibody, M701, for the treatment of malignant ascites due to epithelial cancer: Interim results of a prospective randomized controlled phase II trial","volume":"42","author":"Lin","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105330_bib60","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40164-025-00727-3","article-title":"Development and clinical trial of M701, an Anti-EpCAM x Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors","volume":"14","author":"Liu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccell.2025.03.010","article-title":"The discrete charm of oncolytic viruses: toward the finish line","volume":"43","author":"Lowenstein","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2026.105330_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002015","article-title":"Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors","volume":"9","author":"Luke","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib64","article-title":"Crosstalk between stromal, immune, and ovarian cancer cells in lipid-rich tumor microenvironment exhibits proliferative features","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051458","article-title":"Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission","volume":"15","author":"Manning-Geist","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105330_bib66","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.10.069","article-title":"A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer","volume":"163","author":"Manyam","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib67","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib68","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/ijgc-2023-005200","article-title":"A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)","volume":"34","author":"Michael","year":"2024","journal-title":"Int J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib69","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib70","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.trecan.2023.11.004","article-title":"It's all about the base: stromal cells are central orchestrators of metastasis","volume":"10","author":"Monteran","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib71","doi-asserted-by":"crossref","first-page":"A407","DOI":"10.1136\/ijgc-2023-ESGO.866","article-title":"#24\u2005A phase 2 study (GOG-3084) OF ADP-A2M4CD8 TCR T-cell therapy, alone or in combination with nivolumab, in patients with recurrent ovarian cancers","author":"Moore","year":"2023","journal-title":"Int. J. Gynecol. Cancer 33"},{"key":"10.1016\/j.critrevonc.2026.105330_bib72","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.1016\/j.ygyno.2024.07.417","article-title":"GOG-3084: a phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers","volume":"190","author":"Moore","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib73","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV ovarian cancer: placebo-controlled randomized phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100821","article-title":"41P Phase I analysis of ubamatamab (MUC16xCD3 bispecific antibody) in patients with recurrent ovarian cancer","volume":"8","author":"Moore","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105330_bib75","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41388-018-0637-x","article-title":"An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment","volume":"38","author":"Motohara","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105330_bib76","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","article-title":"Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1","volume":"72","author":"Mun","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105330_bib77","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1117208109","article-title":"Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients","volume":"109","author":"Odunsi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2026.105330_bib78","first-page":"TPS3094","article-title":"A phase I\/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891)","volume":"35","author":"Odunsi","year":"2017"},{"key":"10.1016\/j.critrevonc.2026.105330_bib79","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1158\/1078-0432.CCR-23-3874","article-title":"Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial","volume":"30","author":"Pakola","year":"2024","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105330_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052925","article-title":"Sindbis virus vaccine platform: a promising oncolytic virus-mediated approach for ovarian cancer treatment","volume":"25","author":"Pampeno","year":"2024","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105330_bib81","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502905","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","volume":"7","author":"Pedersen","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105330_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071681","article-title":"Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers","volume":"14","author":"Pena-Romero","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105330_bib83","doi-asserted-by":"crossref","first-page":"A28","DOI":"10.1136\/ijgc-2022-igcs.51","article-title":"7\/#178\u2005Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFN beta induces an anti-tumor immune response in a high grade serous ovarian cancer mouse model","volume":"32","author":"Peters","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101056","article-title":"Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNbeta induces an anti-tumor immune response in high grade serous ovarian cancer","volume":"57","author":"Peters","year":"2024","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105330_bib85","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003190","article-title":"Safety and efficacy of dendritic cell-based immunotherapy DCVAC\/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial","volume":"10","author":"Rob","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.semcancer.2022.03.027","article-title":"Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment","volume":"86","author":"Schoutrop","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib88","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105330_bib89","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1158\/2326-6066.CIR-24-0852","article-title":"Adaptive NK cells exhibit tumor-specific immune memory and cytotoxicity in ovarian cancer","volume":"13","author":"Sun","year":"2025","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.critrevonc.2026.105330_bib90","doi-asserted-by":"crossref","first-page":"S576","DOI":"10.1016\/j.annonc.2024.08.821","article-title":"760P Cadonilimab with neoadjuvant chemotherapy in advanced ovarian cancer patients (AK104-IIT-003): an open, prospective, single arm, phase II trial","volume":"35","author":"Tang","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib91","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn0881","article-title":"CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer","volume":"10","author":"Tarannum","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105330_bib92","doi-asserted-by":"crossref","first-page":"A074","DOI":"10.1158\/1538-7445.OVARIAN23-A074","article-title":"Abstract A074: Maveropepimut-S, a DPX-based immune-educating therapy, combined with Pembrolizumab and Cyclophosphamide in recurrent ovarian cancer, results from the Phase 1\/2 PESCO Trial","volume":"84","author":"Veneziani","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105330_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007697","article-title":"Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer","volume":"11","author":"Verdegaal","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103557","article-title":"50P Vididencel, a cell-based cancer vaccine, induces tumor-directed immune responses in high-grade serous ovarian carcinoma patients","volume":"9","author":"Vledder","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.critrevonc.2026.105330_bib95","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1200\/JCO.2025.43.16_suppl.5566","article-title":"Successful induction of tumor-directed immune responses in high grade serious ovarian carcinoma patients after primary treatment using a whole tumor cell vaccine","volume":"43","author":"Vledder","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib96","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","article-title":"Drug resistance in ovarian cancer: from mechanism to clinical trial","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib97","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40364-025-00818-7","article-title":"Therapeutic landscape of ovarian cancer: recent advances and emerging therapies","volume":"13","author":"Wang","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.critrevonc.2026.105330_bib98","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2096362","article-title":"Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer","volume":"11","author":"Wang","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105330_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217588","article-title":"Enhancing the antitumor effect of MUC16 CART cells in ovarian cancer: the potential of oncolytic adenovirus","volume":"616","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105330_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216267","article-title":"Lipid metabolism reprogramming of CD8(+) T cell and therapeutic implications in cancer","volume":"567","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2026.105330_bib101","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13048-025-01831-y","article-title":"T-cell receptor therapy in ovarian cancer: concepts and challenges","volume":"18","author":"Wang","year":"2025","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.critrevonc.2026.105330_bib102","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/s12967-025-06643-8","article-title":"Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105330_bib103","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/s12967-025-06508-0","article-title":"Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2026.105330_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: from immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2026.105330_bib105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","article-title":"Global epidemiology of epithelial ovarian cancer","volume":"21","author":"Webb","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib106","first-page":"TPS2682","article-title":"Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA)","volume":"43","author":"Wenham","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105330_bib107","first-page":"5524","article-title":"Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts","volume":"42","author":"Wu","year":"2024"},{"key":"10.1016\/j.critrevonc.2026.105330_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116349","article-title":"CAR-T therapy for ovarian cancer: Recent advances and future directions","volume":"226","author":"Xin","year":"2024","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.critrevonc.2026.105330_bib109","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13073-024-01405-5","article-title":"Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study","volume":"16","author":"Xu","year":"2024","journal-title":"Genome Med"},{"key":"10.1016\/j.critrevonc.2026.105330_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663379","article-title":"Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition","volume":"12","author":"Yeku","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106471","article-title":"Tumor associated macrophages in the molecular pathogenesis of ovarian cancer","volume":"84","author":"Yousefzadeh","year":"2020","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib112","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105330_bib113","article-title":"Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1\/CTLA-4 bispecific): a case report and literature review","volume":"60","author":"Zhang","year":"2025","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105330_bib114","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105330_bib115","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression?","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.critrevonc.2026.105330_bib116","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1038\/s41467-025-60239-w","article-title":"A cowpea mosaic virus adjuvant conjugated to liposomes loaded with tumor cell lysates as an ovarian cancer vaccine","volume":"16","author":"Zhao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105330_bib117","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1186\/s12951-024-02744-6","article-title":"Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer","volume":"22","author":"Zhou","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.critrevonc.2026.105330_bib118","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70082","article-title":"Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 x CD3 bispecific antibody) in patients with recurrent ovarian cancer","volume":"17","author":"Zhu","year":"2024","journal-title":"Clin. Transl. Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:04:21Z","timestamp":1780038261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":118,"alternative-id":["S1040842826002179"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105330","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in current and emerging immunotherapies for ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105330"}}